Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews.

Mario CrucianiIlaria PatiFrancesca MasielloSimonetta PupellaVincenzo De Angelis

Published in: The Journal of antimicrobial chemotherapy (2023)

There is low to moderate certainty of evidence from SRs that nirmatrelvir/ritonavir reduces mortality, clinical progression and hospitalization rate in COVID-19 patients compared with controls, without increasing the occurrence of overall and serious adverse events. Based on the overall methodological assessment, on average we can have high confidence in the quality of results generated by the SRs.

Keyphrases

sars cov
coronavirus disease
systematic review
antiretroviral therapy
risk assessment
high intensity
respiratory syndrome coronavirus
risk factors
quality improvement
randomized controlled trial
cardiovascular disease